Krystal Biotech (NASDAQ:KRYS) Reaches New 12-Month High – What’s Next?

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) hit a new 52-week high on Wednesday . The stock traded as high as $319.60 and last traded at $315.5830, with a volume of 71079 shares changing hands. The stock had previously closed at $309.75.

Wall Street Analysts Forecast Growth

KRYS has been the topic of several recent research reports. Jefferies Financial Group boosted their price target on shares of Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Weiss Ratings raised shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, April 9th. Citigroup boosted their price target on shares of Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Wolfe Research initiated coverage on shares of Krystal Biotech in a research report on Friday, March 27th. They set a “peer perform” rating on the stock. Finally, Guggenheim boosted their price target on shares of Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $324.11.

Krystal Biotech Price Performance

The company has a market capitalization of $9.23 billion, a PE ratio of 41.79 and a beta of 0.53. The stock’s 50 day simple moving average is $284.68 and its 200-day simple moving average is $266.01.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.38. The business had revenue of $116.36 million for the quarter, compared to analysts’ expectations of $112.11 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. On average, equities analysts predict that Krystal Biotech, Inc. will post 7.83 earnings per share for the current year.

Insider Activity

In related news, EVP John Charles Thomas sold 642 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total transaction of $193,903.26. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the sale, the insider owned 1,378,155 shares in the company, valued at $424,623,337.05. The trade was a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Krystal Biotech

A number of large investors have recently made changes to their positions in KRYS. Bessemer Group Inc. increased its stake in shares of Krystal Biotech by 106.9% during the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock worth $26,000 after buying an additional 77 shares during the period. Sound Income Strategies LLC increased its stake in Krystal Biotech by 1,270.0% in the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock valued at $34,000 after purchasing an additional 127 shares during the last quarter. Western Wealth Management LLC purchased a new position in Krystal Biotech in the first quarter valued at approximately $34,000. Greenline Wealth Management LLC purchased a new position in Krystal Biotech in the fourth quarter valued at approximately $34,000. Finally, Danske Bank A S purchased a new position in Krystal Biotech in the third quarter valued at approximately $35,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.